The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.49
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.98 (16.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 6.49
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Plantic Technologies, Acal, Anglesey

Thu, 29th Jul 2010 12:51

Shares in Plantic Technologies soared more than 50% after the biodegradeable plastics outfit agreed an 8p per share offer from a company controlled by Gordon Merchant, one of its directors. Acal, which provides technology products and services across Europe and South Africa, said underlying sales for the first quarter increased by around 20% year on year and orders, a measure of current demand, increasing by 29%.Anglesey Mining is up on news that its 41% owned associate company Labrador Iron Mines received approvals to commence construction of its mining facilities from the government of Newfoundland and Labrador.Shares in bakery ingredients maker Real Good Food fell back after it reported good trading at its businesses, though the sugar business was impacted by lower prices.Shares in office space provider Serviced Office climbed after it reported a widening in losses but said that recent changes including opening new buildings and developing a sales team should augur a return to profit.In the half year to June 30, pre-tax losses widened to £272,000 from £207,000 over the same period the previous year, even as revenues jumped to £4.6m from £3.3m.'The changes we have made, coupled with the result to date, indicate a future return to profitability and I have great confidence in continued improvement going forwards,' said chairman Michael Kingshott.Respiratory drug discovery and development company Synairgen posted a pre-tax loss of £2.9m in the year to June 30, more than the £2.8m deficit the previous year as it continued its R&D programme.
More News
20 Jan 2021 21:16

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

IN BRIEF: Synairgen Recruits Covid-19 Patients Into Phase II Trial

Read more
13 Jan 2021 10:24

Synairgen Doses First Patient In Covid-19 Treatment Trial

Synairgen Doses First Patient In Covid-19 Treatment Trial

Read more
11 Jan 2021 20:54

COVID SCIENCE-COVID-19 patients still have symptoms 6 months later; interferon may be helpful treatment after all

By Nancy LapidJan 11 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.Half a year later, COVID-19 pat...

Read more
18 Dec 2020 12:08

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

LONDON MARKET MIDDAY: FTSE 100 Rises As Crunch Brexit Talks Dent Pound

Read more
18 Dec 2020 11:06

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Synairgen Gets Fast Track Designation From US FDA For Covid-19 Vaccine

Read more
18 Dec 2020 10:29

Synairgen makes solid progress with Covid-19 treatment

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its phase 3 trial design evaluating SNG001 as a treatment for patients with Covid-19 on Friday, as well as positive progress on its regulatory path.

Read more
18 Nov 2020 13:59

finnCap Interim Profit More Than Doubles; Chair To Step Down

finnCap Interim Profit More Than Doubles; Chair To Step Down

Read more
13 Nov 2020 14:28

Synairgen surges on positive results for Covid-19 treatment

(Sharecast News) - Synairgen shares surged on Friday after data from trials of its inhaled Covid-19 treatment, SNG001, published in The Lancet Respiratory Medicine, showed positive results in hospitalised patients.

Read more
13 Nov 2020 10:24

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Synairgen Drug Helps Recovery In Hospitalised Covid-19 Patients

Read more
2 Nov 2020 20:03

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

UK TRADING UPDATE SUMMARY: Sensyne App Used In Oxford Covid Study

Read more
15 Oct 2020 11:39

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Synairgen Raises GBP80 Million In Placing, To Launch Open Offer

Read more
14 Oct 2020 18:02

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

IN BRIEF: Synairgen Looks To Raise GBP80 Million For SNG001 Trial

Read more
29 Sep 2020 12:14

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Synairgen Progresses Covid-19 Treatment As Expenses Increase

Read more
9 Sep 2020 16:04

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

IN BRIEF: Synairgen Makes Inhaled Interferon Beta Patent Application

Read more
9 Sep 2020 12:23

Synairgen files for another patent on 'SNG001'

(Sharecast News) - Respiratory drug development company Synairgen updated the market on its intellectual property for the wholly-owned inhaled interferon beta asset 'SNG001' on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.